Skip to main content
Premium Trial:

Request an Annual Quote

Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development

NEW YORK – Chinese genomic testing firm Genetron Health said Monday that it has partnered with Impact Therapeutics to support the firm's anti-cancer drug development efforts.

The two companies plan to work together to discover new targets and develop companion diagnostics for a class of drugs called synthetic lethal inhibitors, which most notably include PARP inhibitors.

Impact CEO Jun Bao said in a statement that the firm has already assembled a large pipeline of DNA damage response drug candidates. The company entered into a CDx partnership with Guangzhou, China-based sequencing firm Burning Rock Biotech for one of these, the PARP inhibitor senaparib.

Working with Genetron, Impact now aims to expand its pipeline further.

"We look forward to leveraging Genetron Health’s experience and resources in the field of precision oncology and working together with them to accelerate the research and development of new drugs, contributing to the global anti-cancer cause," Bao added.

Financial terms of the deal were not disclosed.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.